Kirin Holdings Company, Limited (KIR.F)
| Previous Close | 13.60 |
| Open | 13.60 |
| Bid | 13.70 x 133200 |
| Ask | 14.10 x 131300 |
| Day's Range | 13.60 - 13.60 |
| 52 Week Range | 12.32 - 14.84 |
| Volume | |
| Avg. Volume | 6 |
| Market Cap | 11.07B |
| Beta (5Y Monthly) | 0.30 |
| PE Ratio (TTM) | 16.39 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.44 (3.23%) |
| Ex-Dividend Date | Jun 27, 2024 |
| 1y Target Est | N/A |
- Business Wire
Kirin iMUSE Immune Care and Healthya Visceral Fat Down will go on sale on Tuesday, November 28!
TOKYO, November 27, 2023--Kirin Holdings Company, Limited (TOKYO:2503) will launch a dual-care functional food supplement Kirin iMUSE Immuno-Care and Healthya Visceral Fat Down on November 28 (Tuesday). This product is a collaboration between Kirin iMUSE, Japan’s first*1 immune care brand, and Kao Healthya, Japan’s first*1 body fat care beverage brand from Kao Corporation (TOKYO:4452), and will be sold at drugstores nationwide and through Kirin Kyowa Hakko Bio mail order.
- Business Wire
Japan’s First Discovery*1 on Visceral Fat and Immune Activity in Joint Research by Kirin Holdings and Kao
TOKYO, November 24, 2023--Kirin Holdings Company, Limited (TOKYO:2503) and Kao Corporation (TOKYO:4452) will participate in the Wakayama Health Promotion Study, a cohort study*2 led by Wakayama Medical University and organized by the Health Promotion Research Center (HPRC), a non-profit organization. Kao and Kirin Holdings conducted a joint study from November 2022 to investigate the relationship between visceral fat and the plasmacytoid dendritic cells (pDC*3) activity*4, which are the command
- Business Wire
Nagasaki University Presented Results Of a Specified Clinical Trial On The Use of L. lactis strain Plasma For Patients With COVID-19
TOKYO, May 11, 2023--Nagasaki University Presented Results Of a Specified Clinical Trial On The Use of L. lactis strain Plasma For Patients With COVID-19
